For instance, the combination of Palbociclib (an oral CDK4/6 inhibitor) and GDC-9545 (an oral SERD) demonstrated significant efficacy in a mouse tumor model, resulting in up to a 24% reduction in tumor size or degradation (Liang et al., 2021). The gene discussed is CDK4; the disease is neoplasm.